Stock markets did not disappoint you in 2021. The various market cap segments delivered textbook-like bull market returns with small caps outperforming midcaps and midcaps outperforming large caps. The Nifty Small 250’s 57% return for the calendar year (ending December 22, 2021) was miles ahead of the Nifty 50’s 23%. 

As you may have guessed, it also means that stocks that many fund managers did not like to hold were the ones that hogged the limelight. Funds that took a swing at such stocks soared above their peers. 

Prime Funds performance

In equity mutual funds, two peculiarities emerged: 

  • One, funds that were underperformers for years together bounced back to the top quartile in the 1-year chart and, in some cases, the return was big enough to pull even 3-returns to the top of the charts. Old timers like HDFC Flexicap that have steadily been in the bottom quartile on consistency metrics were among the chart toppers this year. Steady performers on the other hand, found themselves wanting in glamour on the returns front. 
  • Two, the divergence in performance of funds was stark. A long-term steady performing fund like SBI Small Cap returned 45.3% this calendar (point to point till Dec. 22), paling in comparison to the more daring ones like Quant Smallcap that showcased a whopping 86% return (point-to-point till Dec. 22). 

This phenomenon is not new and is true of every bull market. As we often repeat, investment decisions made in these markets can go wrong if we rely excessively on near-term moves. Hence, we would caution you not to get too swayed by the churn in the performance chart. 

As far as the debt market goes, there’s little to write about in terms of returns or trends. Across categories, returns turned and held at lower levels as the RBI kept rates on pause. Duration opportunities, which had held up returns in earlier years, also waned leaving investors with a prolonged stagnant interest rate period. The debt space did see the emergence of target-maturity passive funds that sparked interest – but the key, as always, lies in the yields.

NEED FOR REBALANCING

While you can wait for our equity outlook for 2022 in January, we would like to bring to your notice that the sharp rally in 2021 calls for a review and rebalancing of your MF portfolio. There is a high chance that many of your investments have breached your original asset allocation by a sizable percentage. For example, our High-Growth Portfolio was designed with 80% equity allocation.

This crossed the 85% mark since the portfolio’s launch in mid-January 2019. The swift rally since the March 2020 correction could have caused many of your portfolios to move far beyond your original allocation. Keep a thumb rule of the allocation exceeding 5% or more of your original allocation and rebalance your portfolio as soon as possible. You can use our asset rebalancing calculator to know how much to rebalance.

For this purpose, since equity is the asset class that has rallied, here are some guidelines. First, exit any long-term equity fund underperformers. Next, book profits in small cap and midcap funds. Deploy this in the debt funds that you hold in that same portfolio. 

While we will be talking about this again when we do our portfolio reviews in January, we would urge you to do this exercise for all your asset-allocated portfolios.

Now we move to assessing how Prime Funds – our list of recommended funds – did across key fund buckets.

How we assessed performance

  • We picked key buckets in our Prime Funds. These are Equity – Moderate, and Equity – Aggressive, Hybrid Equity – Moderate risk, Thematic/sector, Very Short-Term Debt, Short-term Debt, Medium-term and Long-term debt (these last two are clubbed). We did not choose passive funds for this exercise of seeing outperformance. 
  • Since we make changes to our list during our quarterly assessment, we have suitably incorporated those in our performance review. The returns were therefore taken for each quarter and the product of the returns taken for the year in reckoning. Returns are therefore not point-to-point for the calendar.
  • For assessing equity fund performance, we compared with appropriate benchmarks. With debt funds, we took only the peer sets as debt indices are either not comparable or data is not available (they are paid indices).
  • Please note that we have taken a portfolio approach to providing the returns as we cannot provide the returns for individual funds (for the full year) as some would have entered or exited our list. But we have mentioned the top performers and those that lagged.

Prime Funds performance – equity funds

Our initial explanation sets the context for our equity fund performance – and so, you will know that our Prime Equity Funds, chosen primarily on consistency in performance, were not a match to the other chart-toppers of 2021. But we did quite well against the indices. That we didn’t have chart toppers does not worry us and at present, we are not swayed by any of the mouth-watering returns funds served up in the 1-year charts.

Equity Moderate

Our Equity – Moderate category beat the Nifty 100 by a good 5 percentage points. Not surprisingly, funds like Parag Parikh Flexicap topped our list followed by Canara Robeco Flexicap (though the former had a significant lead over the latter). Funds such as Axis Bluechip or Kotak Flexicap that faltered during the early part of the year (when the rally was strong) are making a good comeback. 

Overall, there aren’t funds in this category that we are worried about at present. The market weakness in the fourth quarter has reinforced our belief that a majority of our funds contain downsides better than the index. Having said this, we take note of the fact that our funds returned about the same as the category average (considering largecap, flexicap, contra and value funds). This has to do with the category average being bumped up by a few outlier funds like SBI Contra or BOI AXA Flexicap that bounced back from poor performance than by our recommended funds underperforming the category.

Equity - Aggressive

Our aggressive funds are not focused only on mid and small cap funds. They are across the large & mid, focused, mid and small cap categories, and even include a broad-based thematic fund. Our approach, even to this category, is to contain downside while looking at index-beating returns on the upside. This is in line with our overarching philosophy of building wealth by containing downside first and picking steady performers instead of the flashy funds. 

As a mix, this Prime category is most comparable to the Nifty Large Midcap 250 index.

Our funds comfortably outpaced 2 of the 4 indices we have mentioned. Funds such as SBI Focused Equity bounced back from last year’s underperformance while others such as DSP Midcap are narrowing the gap of underperformance. 

However, our mid-and-smallcap funds undershot their benchmarks for the year. But then, not many funds from the mid and small-cap categories outperformed their index in the first place. This is because the quality of stocks that rallied in the present market do not provide much scope for a fund manager to hold them in a fundamental-driven portfolio. 

Considering the category average itself, if you combine the various categories that we classify as aggressive, the average was 47.6%. That’s 3.6 percentage points higher than our funds, even if they are also below the mid-and-small cap indices mentioned above. 

However, as we mentioned earlier in this article, our relative underperformance to the category is hardly a surprise. Given the wild returns in funds such as PGIM Midcap Opportunities in the midcap space of BOI AXA Smallcap and Quant SmallCap in the small-cap segment, our own recommended funds’ returns will certainly look pale. We do think these performances will normalize. For those of you who hold such outlier funds, the present levels are a clear signal to book profits and prune exposure or even exit based on our MF review tool calls.

Equity – Sector/theme funds

Not many of you may have noticed that Prime Funds also carries select sector or theme calls. This year, we got several of those right (we don’t always😊). Commodities, IT and infrastructure themed funds delivered well (in the range of 57-73% annualized returns) outperforming the broad market index Nifty 500 anywhere between 20-36 percentage points. 

We entered pharma and healthcare (after missing it in early 2020) when we thought it had corrected sufficiently to warrant an entry - but we see that it still remains less favoured. We are hopeful our entry point will work in your favour and think that the fund can be averaged on market falls. 

Our call on MNC did not go well as the fund is not one for a bull market. Expecting a correction, we had brought it in but pulled it out in our September quarter review. We prefer our FMCG funds to act as the defensive theme. Our 2 banking funds remained the primary underperformers in this space and dragged overall returns.

Prime Funds performance - Hybrid equity moderate risk

In our recommendations for the Hybrid Equity Moderate Risk bucket, we have two aggressive hybrid funds and one balanced advantage fund that can have a higher unhedged equity exposure than peers (i.e., relatively more aggressive in the DAA/BA category).

For hybrid aggressive funds, we do consider performance against the Nifty 50 Hybrid Composite Debt 65:35 index. But because funds often go outside the Nifty 50 stocks and can have higher equity allocations, we primarily look at category averages. In balanced advantage funds, too, we find category comparison to be a better approach. 

Our recommendations have been in line with the category average, as shown below:

The reasons for being in line with the category and not superior are both because of our approach in this category and due to quirks in the category average. 

In our hybrid fund recommendations, our primary intention is to keep downside risks low as these funds are meant for conservative investors who want equity funds but are uncomfortable with swings in returns or steeper losses. In neither case do we want to recommend funds with very aggressive strategies.

Hybrid aggressive funds with significant mid and small-cap exposure will not find a place in our list. Therefore we lost out to funds that took significant mid-cap/small-cap exposure such as Baroda Hybrid Equity, BOI AXA Mid and Small Cap Equity & Debt, or IDFC Hybrid Equity or to funds with limited track record such as Quant Absolute. Funds such as these skew the average, due to the sheer extent of outperformance. Our recommended funds did better than at least half the category. 

This apart, several funds that scored in 2021 were also very inconsistent performers both short-term and long-term. Take Kotak Equity Hybrid, for instance. This fund has done well in this calendar, but has been able to beat the index less than 20% of the time on a 3-year basis.

In the balanced advantage category, our recommended fund ICICI Pru Balanced Advantage has delivered better than most balanced advantage funds despite its conservative stance relative to peers such as Edelweiss or HDFC. 

Our stance is also clear if you consider the final quarter of 2021 – a turbulent period for stock markets. Here, ICICI Pru Balanced Advantage ranks among the top in our category, while the more aggressive funds mentioned above have slid more as they were more open to equity market risks. We will continue to prioritize downside containment in this category.

Prime Funds performance - Debt funds

The debt fund space, overall, has been a sedate one for 2021. With the RBI holding off on raising rates to spur economic growth and keep government borrowing costs under control, higher yields from accrual funds stayed low. The will-it-wont-it back and forth over rates also kept out opportunities in duration, which had otherwise compensated for low accrual return earlier in 2019 and 2020. 

That meant returns from both accrual and duration took a step back over 2021 – and the subsequent low return has disappointed most of you. We had outlined strategies you can follow in debt investments, even outside of debt funds, given this stagnant rate scenario, last month. While we will issue an outlook for debt funds and market next month, it’s worth noting that portfolio yields for funds have been slowly inching marginally up. Bond yields have begun rising, some banks have increased FD rates, while the US has indicated rate hikes in 2022. All this suggests that this prolonged period of low returns – a first for debt funds – may be drawing to a close.

Debt – very short term

Against the scenario of low yields, we’re comfortable with the performance of our recommended funds in the very short term category compared to peers.

Yes, the outperformance of our recommendations is not much. However, do note that in debt funds, generally, big out performances aren’t possible since interest rate differentials are limited. Any high return outperformance within a category would either come from credit risks or from duration. Given the stagnant rate scenario over 2021, etching out significant outperformance is harder. 

Our recommendations in the Very Short-Term bucket are skewed towards money market funds (with commercial papers and certificates of deposits). That meant holding instruments with very low-risk with low yields. Other funds from the very short-term category could hold corporate bonds that were close to maturity and could earn marginally higher yields or take credit risks. Given this, the small outperformance that our recommended funds have delivered holds up well. Several funds that clocked performance significantly better than our recommendations, such as Aditya Birla SL Low Duration or HDFC Low Duration, tended to have at least some holding in lower-rated papers. 

Should the rate cycle reverse higher, CPs and CDs will serve up better yields which can push returns back up. In any case, money market, ultra-short and low duration funds tend to go through phases based on yields and opportunities, as we explained in this article (see Trend #1).

Debt – Short term

Against the scenario of low yields, our recommendations have done well compared to peers.

Our recommended funds have beaten the category average by a small margin. Here too, we are comfortable with the calls we have taken and the returns they have delivered. 

We took the call to step up recommendations in floating rate funds, which are positioned more favourably compared to other categories in an uncertain rate scenario. We added Nippon Floating Rate to join HDFC Floating Rate. These funds presented a mix of longer-maturities, shorter maturities, and measured credit risk. This paid off as floating rate funds delivered marginally better than other categories. However, do note that the floating rate category, while a good one to hedge interest rate calls, may not always be an outperformer.

Our recommended funds beat about two-thirds of the funds in the banking & PSU debt, short duration, and floating rate categories. They underperformed funds that dipped into credit risks, such as Aditya Birla SL Short Term, Baroda Short Term and so on, and did not match up on other metrics we consider as well. We opted for HDFC Short Term to allow better returns through controlled credit risk, and this has been among the best performers in the categories for 2021. 

Our two banking & PSU funds – Axis and IDFC - have been the ones to undershoot, given the nature of the papers funds in this category invest in. A fund that we did not recommend, Edelweiss Banking & PSU, was a significant outperformer. It tends to actively manage duration to shore up returns; however, we prefer more stable maturities for this timeframe.

Debt – Medium & Long Term

In these two Prime Fund buckets – Medium Term and Long Term – we were a shade more active. For starters, in January, we removed Franklin India Corporate Bond from our recommended list. This apart, we took a cautious step towards introducing credit risk recommendations, as the time frame allowed for such risks, the spread of the lower-rated papers offered over AAA and gilt papers was attractive, and there were few options for superior long-term returns in the debt space. We continued to avoid funds or categories that took duration calls, apart from our gilt - constant maturity pick.

Our recommendations have fared well compared to peers.

Our corporate bond fund recommendations – ABSL, HDFC, ICICI, and Kotak – have all outdone their category average and we’re happy with our recommendations here. With returns of 4.2%-4.5% for 2021 (until December 15), it is a good margin over the 3.9% for the category. 

Our credit risk addition midway through the year, in ICICI Pru Credit Risk, is holding up well. Taking some risk where the time frame allows, and a favorable market scenario will help improve returns. We have opted for a fund that has managed risks well. 

On the other hand, SBI Constant Maturity has fared poorly in terms of absolute returns, though it has still delivered better than other constant maturity funds. The constant maturity category, in general, has done even worse than very short-term categories at just about 3% for this calendar. With no further rate cuts and stagnant rates, returns from duration tapered off. Returns will continue to languish even when the rate cycle turns up, as is the nature of this category. However, this remains a solid option for long-term portfolios, as the movements of rate upcycles and downcycles even off.

We are also seeing a marginal uptick in returns towards the end of the year for several debt fund categories. So, while returns currently look unsatisfactory, a rate up move, that is widely expected, can make 2022 a year of debt. We have also made one-off recommendations in target-maturity funds when the opportunity arose in terms of yields and we’ll continue to do so more actively in 2022.

More like this

14 thoughts on “Prime Funds performance in 2021”

  1. Thanks for an honest assessment of the performance. Pl can you include the aspect of Fund manager performance f your chosen funds.

  2. Great job Vidya Bala and Bhavana Acharya. Liked the transparency and the straight forwardness in the analysis that is not only looking at the past but with an eye on the future. Keep it up
    PS – in the new MF selection tool, pl add columns of yearly and/or 3 year return..without that, the result is incomplete.

  3. If I subscribe what returns should I expect for my investment either in Equity, Debt Fund, CAGR through MF SIP or through any other investments option. Can you please guide

    1. We don’t give expected returns – one, it is not possible to predict returns, and returns change over time. Two, regulations bar us from providing this. In our recommendations, our aim is to offer returns that beat the market. You can understand more about returns and expectations in these articles:
      https://www.primeinvestor.in/what-is-risk-premium-and-how-to-use-it/
      https://www.primeinvestor.in/are-your-returns-expectations-right-heres-how-to-find-out/
      Thanks, Bhavana

  4. Looks great and can you shown the list of individual performance of funds which guided by prime like stocks return as on date,so it will be useful for us.

    1. Unfortunately, like we mentioned in the article, given that some are removed and some added in between putting them in one list won’t be comaprable, we annualise them with sum product and the same may look confusing. hence refrained. Also, unlike stocks, there is no concept of reco date in MFs. We simply take the calendar year for some common comparison as funds remain a buy at any NAV as long as their are consistent. thanks. Vidya

  5. Will there be such review for ready to use portfolios? I am particularly interested in time based portfolio (> 7 years).

        1. Your suggestion is noted, but it’s a very tough thing to do given that the portfolio undergoes changes. This apart, our portfolios themselves are 2 years old now (we launched in Jan 2020), so showing returns prior to this period would not be right. – thanks, Bhavana

Comments are closed.

Hold On

You are being redirected to another page,
it may take a few seconds.
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

Start registration

Start registration

OR
user icon
user icon
user icon

Terms & Conditions

A copy of the T&C has been sent to your email.

Last modified on February 18, 2025

This website www.primeinvestor.in (“Website”) is owned and operated by PrimeInvestor Financial Research Pvt. Ltd. (“RA”), a SEBI-registered Research Analyst with Registration No. INH200008653.

Through the Website, the RA allows clients to access research recommendations, research reports, and model portfolios, along with tools, personal finance products, and articles, on the payment of a subscription fee (“Research Services”). The terms ‘RA’ or ‘us’ or ‘we’ refer to PrimeInvestor Financial Research Pvt Ltd (SEBI RA Registration No INH200008653) who are the owners of this Website and offering the Research Services. The term ‘you’ and ‘client’ refers to the subscriber of the Services on the Website. The RA provides the Research Services subject to the notices, terms, and conditions set forth in these Terms. By accepting these Terms when you subscribe to the Research Services, you provide your consent to abide by these Terms.

Most Important Terms and Conditions (MITC)

[Forming part of the Terms and Conditions for providing research services]

  1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
  2. The fee charged by RA to the client will be subject to the maximum amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
    Note:
    • SEBI's current cap on fee is Rs 1,51,000/- per annum per family of client for all research services of the RA.
    • The fee limit does not include statutory charges.
    • The fee limits do not apply to a non-individual client / accredited investor.
  3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for the unexpired period.
  4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
  5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
  6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
  7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
  8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
  9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
  10. For any grievances,
    • Step 1: the client should first contact the RA using the details on its website or following contact details:
      Customer care: [email protected]
      Grievance officer: [email protected], ATTN: Srikanth Meenakshi
      Compliance officer: [email protected], ATTN.: Bhavana Acharya
      Principal officer: [email protected], ATTN.: Vidya Bala
    • Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
    • Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in
  11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
  12. The RA shall never ask for the client’s login credentials and OTPs for the client’s Trading Account, Demat Account, and Bank Account. Never share such information with anyone including RA.

By browsing, viewing, using the Website and subscribing to the Research Services provided therein you consent to and agree to comply with these Terms and Conditions of subscription (“Terms”).

The RA reserves the right to change or modify the Website, the contents thereof and these Terms at any time. All modifications to these Terms & Conditions will be posted on the Website and will become effective immediately upon such posting. Changes once made will be communicated to the client. Continued use of the Website shall be construed as acceptance of the revisions to the Terms by conduct.

The following terms and conditions include but are not limited to minimum mandatory terms and conditions to clients as stipulated by SEBI.

1. Availing the research services

By accepting delivery of the research service, the client confirms that he/she has elected to subscribe to the research service of the RA at his/her sole discretion. The RA confirms that Research Services shall be rendered in accordance with the applicable provisions of the SEBI RA Regulations.

2. Obligations on RA

The RA shall be bound by the SEBI Act and all the applicable rules and regulations of SEBI, including the RA Regulations and relevant notifications of Government, as may be in force, from time to time.

3. Client Information and KYC

The client shall furnish all such details in full as may be required by the RA in its standard form with supporting details, if required, as may be made mandatory by Research Analyst Administration and Supervisory Body(RAASB)/SEBI from time to time. RA shall collect, store, upload and check KYC records of the clients with KYC Registration Agency (KRA) as specified by SEBI from time to time.

4. Standard Terms of Service

The consent of client shall be taken on the following understanding:

“I / We have read and understood the terms and conditions applicable to a research analyst as defined under regulation 2(1)(u) of the SEBI (Research Analyst) Regulations, 2014, including the fee structure.

I/We are subscribing to the research services for our own benefits and consumption, and any reliance placed on the research report provided by research analyst shall be as per our own judgement and assessment of the conclusions contained in the research report.

I/We understand that –

  1. Any investment made based on the recommendations in the research report are subject to market risk.
  2. Recommendations in the research report do not provide any assurance of returns.
  3. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report.”

The declaration of the RA is as follows:

  1. We are duly registered with SEBI as an RA pursuant to the SEBI (Research Analysts) Regulations, 2014 and our registration details are: registration no SEBI INH200008653, with registration date 19th August, 2021
  2. We have the registration and qualifications required to render the services contemplated under the RA Regulations, and the same are valid and subsisting;
  3. Research analyst services provided by us do not conflict with or violate any provision of law, rule or regulation, contract, or other instrument to which it is a party or to which any of its property is or may be subject;
  4. The maximum fee that may be charged by the RA is ₹1.51 lakhs per annum per family of client. Our current fee structure, the term and duration of our subscription for our Research Services, can be viewed on our website here: https://primeinvestor.in/prime-pricing
  5. The recommendations provided by us as part of the Research Services do not provide any assurance of returns.

5. Consideration and mode of payment

The client shall duly pay to the RA the agreed fees for the services that RA renders to the client and statutory charges, as applicable. Such fees and statutory charges shall be payable through the specified manner and mode(s)/ mechanism(s).

The payment of fees shall be through a mode that shows traceability of funds. Such modes include but are not limited to credit cards/debit cards/ UPI/ net banking or any other mode specified by SEBI from time to time. However, the fees shall not be in cash.

6. Risk factors

  1. Investments are subject to market risk. Investing or trading in financial products involves risk. Past performance of the recommendation is not an indication of future returns. Past performance of the RA is not an indicator of future performance. Past performance of the security is not an indication of future returns.
  2. There are no assurances or guarantees that the objectives of any investment in financial products will be achieved.
  3. The names of financial products mentioned herein do not in any manner indicate their prospects or returns. The performance in the equity may be adversely affected by the performance of individual companies, changes in the market place and industry specific and macro-economic factors.
  4. The performance of the investments/ products recommended by the RA are subject to a wide range of risks, including but not limited to: performance of the respective companies, changes in equity and debt market conditions, micro and macro factors and forces affecting equity and debt markets, general levels of interest rates and interest rate risk, credit risk, liquidity risk, reinvestment risk, economic slowdown, volatility & illiquidity of the stocks, risks associated with trading volumes, liquidity and settlement systems in equity and debt markets and/or such other circumstance beyond the control of the RA or any of its Associates.
  5. Other risk factors include that may affect the performance of the investments/ products recommended by the RA include but are not limited to economic policies, changes of Government and its policies, acts of God, acts of war, civil disturbance, sovereign action and /or such other acts/ circumstance beyond the control of the RA or any of its Associates.
  6. The recommendations provided by the RA as part of its Research Services may not be suitable to all categories of investors.
  7. The client should read all scheme and security related documents carefully before investing.
  8. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

7. Conflict of interest

The RA shall adhere to the applicable regulations/ circulars/directions specified by SEBI from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

General disclosures: PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). PrimeInvestor Financial Research Pvt. Ltd., its employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

Restrictions on trading: To ensure no conflict of interest, the RA declares as follows:

  1. Personal trading activities of the individuals employed as research analysts shall be monitored, recorded and subject to a formal approval by the directors or compliance officer of PrimeInvestor Financial Research Private Limited.
  2. Research analysts employed by PrimeInvestor Financial Research Private Limited or their associates or relatives shall not:
    • Deal/ trade in stocks recommended/ tracked by the research analyst within 30 days before and five days after the publication of a research report;
    • Deal/ trade in securities that the research analyst reviews in a manner contrary to the given recommendation;
    • Purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends.

Disclosures with respect to Research and Recommendations Services:

  1. The RA or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation.
  2. The RA, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its Research Services or investment information.
  3. The Research Analysts who have prepared the research reports that form part of the Research Services (“Research Analyst”) certify that all of the views expressed in the research report accurately reflect their views about the subject company or subject security.
  4. The RA or directors or employees or Research Analyst certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
  5. The Research Analyst has not served as director, officer or employee in the subject company, AMC or insurance company of the mutual fund or insurance policy that is the subject of this report, or company whose bonds, NCDs, fixed deposits or other savings products that is the subject of this report.
  6. The Research Analyst or their relatives do not have any known direct or indirect material conflict of interest including long/short positions in the subject company.
  7. The Research Analyst may hold investments in the stocks, mutual fund schemes, bonds, fixed deposits, insurance policies, or other products that are the subject of the recommendations provided as part of the Research Services. The Research Analyst certifies that they will not act in a manner contrary to their views on these securities except in the event of significant news or event or change in personal financial circumstances and without formal approval from the directors of PrimeInvestor Financial Research Pvt. Ltd. or the compliance officer.
  8. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of the Research Services. Such conflict of interest shall be disclosed to the client as and when they arise.
  9. The RA or its directors or its employee or its associates have not managed or co-managed the public offering of any company. The RA or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. The RA or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. The RA or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation.
  10. The subject company of its research recommendations was not a client of the RA or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided.
  11. The RA or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.

PrimeInvestor Financial Research Pvt. Ltd., its Associates, the Research Analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies)? – NO

8. Termination of service and refund of fees:

The RA may terminate or suspend rendering of Research Services to the client in the following circumstances:

  1. On account of suspension/cancellation of registration of RA by SEBI. In case of suspension of certificate of registration of the RA for more than 60 (sixty) days or cancellation of the RA registration, RA shall refund the fees, on a pro rata basis for the period from the effective date of cancellation/ suspension to end of the client’s subscription period.
  2. The RA voluntarily chooses to terminate its Research Service. In the event of such termination of the Research Service, the RA shall refund the fees, on a pro rata basis for the period from the date of such termination of research service to end of the client’s subscription period.

9. Grievance redressal and dispute resolution:

Any grievance related to:

  1. nonreceipt of research report, or
  2. missing pages or inability to download the entire report, or
  3. any other deficiency in the research services provided by RA

shall be escalated promptly by the client to the person/employee designated by RA, in this behalf as under:

Name: Bhavana Acharya
Designation: Director & Compliance Officer, PrimeInvestor Financial Research Pvt Ltd
Email: [email protected]

The RA shall be responsible to resolve grievances within 7 (seven) business working days or such timelines as may be specified by SEBI under the RA Regulations.

RA shall redress grievances of the client in a timely and transparent manner. Any dispute between the RA and his client may be resolved through arbitration or through any other modes or mechanism as specified by SEBI from time to time.

If the client is not satisfied with the response of the RA, he/she can lodge his/her grievances with SEBI at scores.sebi.gov.in. Alternatively, the client may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575

Details on grievances are available on the Website as follows: https://primeinvestor.in/ra-grievance/

10. Additional clauses:

Scope of the Research Service: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Services are not meant to be tailor-made or customized solutions that specifically apply to each client based on his/her risk profile.

The RA never guarantees the returns on the recommendation provided. Investor shall take note that investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The RA shall not be responsible for any loss to the Investors.

This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.

The Research Service, including recommendations, research reports, updates, and other information will be accessible through the RA’s website https://primeinvestor.in only. Such recommendations and updates will not be provided over phone calls.

Fees: Our current fee structure, the term and duration of our subscription for our Research Service, can be viewed on our website: https://primeinvestor.in/prime-pricing. Eligibility for any discounts is ascertained at the time the client subscribes. Any such discount and its tenure shall be at the discretion of the RA.

Subscription and access to content services fall under the purview of Goods and Services Tax (GST) as per the current indirect taxation policy, Government of India. Unless otherwise indicated, prices stated on our website are exclusive of applicable GST, any applicable value added tax (VAT) or other sales taxes. We are a business-to-consumer (B2C) service provider and we do not commit to provide any input tax credit on GST charged on subscription to our Research Service.

We may change the Subscription Fees and charges then in effect, or add new fees or charges which will take effect at the end of the client’s subscription period, by giving notice in advance and an opportunity to cancel renewal of the subscription.

Subscription Access & Renewal: Subscription to the Website commences immediately on the realisation of payment of the Subscription Fees. Subscriptions are set to be renewed automatically at the end of the subscription period.

Unless the client notifies us before the end of his/her subscription period, or the client cancels the auto-renewal mandate within the period specified by law, that the client does not wish to renew his/her subscription, the client’s subscription will renew for the period defined by the client’s subscription plan. We will charge the subscription using the same payment method that you previously used.

Although the client may notify to us his/her intention to his/her subscription, such notice will only take effect at the end of his/her then current subscription period, and he/she will not receive a refund other than as set out under Clause 8 in these Terms.

The client may notify us of his/her wish to cancel his/her subscription by sending an email to [email protected]. The client must provide at least 5 business days advance notice for this to be implemented.

Refunds: There can be no cancellation and refund of subscription fee paid once the subscription is active, other than as stated in Clause 8 of these Terms. If the client is entitled to a refund as specified under Clause 8 of these Terms, the RA will credit that refund to the card or other payment method used by the client to submit payment, unless it has expired - in which case the RA will contact the client to proceed with the refund. If we do issue a refund or credit due to circumstances outside the obligations specified under Clause 8, we are under no obligation to issue the same or a similar refund in the future.

General disclaimers: The recommendations made herein in the Research Services are expression of views and/or opinions and should not be deemed or construed to be advice for the purpose of purchase or sale of any security, nor a solicitation or offering on any investment/ trading opportunity on behalf of the company, AMC, insurance company, or issuer of security referred to herein.

The content and research reports generated by the RA does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities.

The information/ opinion/ views mentioned in research reports or by the RA are not meant to serve as a professional guide to the client or recipients of this Report. The research report, recommendation, or any other content published by the RA do not assure or guarantee any minimum or fixed returns to the client or recipients of the reports/ recommendations/ content.

Use of this information is at the client’s own risk. The client must make his/ her own investment decisions based on his/her specific investment objective and financial position and using such independent advisors as he/she believes necessary. The services rendered by the RA are on a best-effort basis. All information in the content or research report of the RA is provided on an as is basis. Information is believed to be reliable but the RA does not warrant its completeness or accuracy and expressly disclaim all warranties and conditions of any kind, whether express or implied.

While due care has been taken to ensure that the disclosures, information, and opinions given are fair and reasonable, PrimeInvestor Financial Research Pvt Ltd and/or none of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/ opinions/ views contained in the research report and recommendations that form part of the Research Service, and/or mails, social media or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

Any agreements, transactions or other arrangements made between the client and any third party named on (or linked to from) the Website are at your own responsibility and entered into at your own risk. Any information that you receive via the Website, whether or not it is classified as “real time”, may have stopped being current by the time it reaches you. Market price information may be rounded up/down and therefore may not be entirely accurate.

The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research Services before onboarding.

History, present business and background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services.

Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made thereunder against the Research Analyst relating to Research Analyst services.

Details of the RA's associates: No associates.

Usage of Website Content: This Website is controlled and operated by the RA. All material, including research reports, recommendations, portfolios, ratings, lists of financial products, illustrations, statements, opinions, views, photographs, products, images, artwork, designs, text, graphics, logos, button icons, images, audio and video clips and software (collectively, “Content”) are protected by copyrights, trademarks and other intellectual property rights that are owned and controlled by the RA or by other parties that have licensed their material to us.

Except where otherwise agreed in writing with the RA, material on the Website is solely for the client’s personal, non-commercial use. Except as provided below, the client must not copy, reproduce, republish, upload, post, transmit or distribute such material in any way, including by e-mail or other electronic means and whether directly or indirectly and the client must not assist any other person to do so.

Without the prior written consent of the RA, modification of the materials, use of the materials on any other web site or networked computer environment or use of the materials for any purpose other than personal, non-commercial use is a violation of the copyrights, trademarks and other proprietary rights, and is prohibited. Any use for which the client receives any remuneration, whether in money or otherwise, is a commercial use for the purposes of these Terms.

The client may occasionally distribute a copy of a research report, or a portion of the same, from the Website in non-electronic form to a few individuals without charge, provided the client includes all copyright and other proprietary rights notices in the same form in which the notices appear, original source attribution, and the phrase “Used with permission from PrimeInvestor Financial Research Pvt. Ltd.”

While the client may occasionally download and store research reports or information from the Website for his/her personal use, he/she may not otherwise provide others with access to the same. The foregoing does not apply to any sharing functionality we provide through the Website that expressly allows the client to share Content or links to Content with others. In addition, the client may not use Content he/she has downloaded for personal use to develop or operate an automated trading system or for data or text mining.

The client agrees not to rearrange or modify the Content available through the Website. The client agrees not to display, post, frame, or scrape the Content for use on another website, app, blog, product or service, except as otherwise expressly permitted by these Terms. You agree not to create any derivative work based on or containing the research products and Content. The framing or scraping of or in-line linking to the Services or any Content contained thereon and/or the use of webcrawler, spidering or other automated means to access, copy, index, process and/or store any Content made available on or through the Services other than as expressly authorized by us is prohibited.

The client further agrees to abide by exclusionary protocols (e.g., Robots.txt, Automated Content Access Protocol (ACAP), etc.) that may be used in connection with the Research Services. The client may not access parts of the Research Services to which he/she is not authorized, or attempt to circumvent any restrictions imposed on your use or access of the Services.

As a general rule, the client may not use the Content, including without limitation, any Content made available through one of our RSS Feeds, in any commercial product or service, without our express written consent.

The client may not create apps, extensions, or other products and services that use our Content without our permission. The client may not aggregate or otherwise use our Content in a manner that could reasonably serve as a substitute for a subscription to the Website.

The client may not access or view the Services with the use of any scripts, extensions, or programs that alter the way the Services are displayed, rendered, or transmitted to you without our written consent.

The client agrees not to use the Services for any unlawful purpose. We reserve the right to terminate or restrict the client's access to the Website if, in our opinion, the client's use of the Services may violate any laws, regulations or rulings, infringe upon another person's rights or violate these Terms.

Prohibited content: The Website includes comments sections, blogs and other interactive features that allow interaction among clients and between clients and the RA. We call the information posted by or contributed by users “Contributed Content.” In the course of availing of the Research Services or uploading any post or comment on the Website, the client shall not post any Contributed Content that (i) contains nude, semi-nude, sexually suggestive photos, (ii) tends or is likely to abuse, harass, threaten, impersonate or intimidate other users of the Website and/or Research Services, (iii) is lascivious or appeals to the prurient interest or if its effect is such as to tend to deprave and corrupt persons who are likely to use or have access to the Website and/or Services, or (iv) otherwise violates, is prohibited or restricted by applicable law, rule or regulation, is offensive or illegal or violates the rights of, harms or threatens the safety of other users of the Website and/or Services (collectively “Prohibited Content”).

We reserve the right to cease to provide the client with the Research Services or access to the Website, or terminate your subscription, with immediate effect and without notice and liability, for violating these Terms, applicable law, rules or regulations and reserves the right to remove Prohibited Content which is in violation of these Terms, or is otherwise abusive, illegal or disruptive. The determination of whether any content constitutes Prohibited Content, violates these Terms, or is otherwise abusive illegal or disruptive, is subject to the sole determination of the Firm.

Changes to Research Services: We are constantly endeavouring to improve the quality of Research Services provided to our clients. Due to this, the form and nature of the Research Services provided may change from time to time without any prior notice to the client. We reserve the right to introduce and initiate new features, functionalities, components to the Website and/or Research Services and/or change, alter, modify, or discontinue existing ones without any prior notice to the client.

Warranty and liability disclaimer: The Website, Research Services, and all the materials and services, included on or otherwise made available to the client through this Website is provided by the RA on an “as is” and “as available” basis without any representation or warranties, express or implied except otherwise specified in writing. Without prejudice to the foregoing paragraph, the RA does not warrant that:

  • This Website and/or Research Services will be constantly available, or available at all;
  • The information on this Website or provided through the Research Services is complete, true, accurate or not misleading; or
  • The quality of any products, services, information, or other material that you obtain through the Website or Services will meet your expectations.

The RA, to the fullest extent permitted by law, disclaims all warranties, whether express or implied, including the warranty of merchantability, fitness for particular purpose and non-infringement. The RA makes no warranties about the accuracy, reliability, completeness, or timeliness of the Website, Research Services, Content, Contributed Content, Services, software, text, graphics and links.

The RA does not warrant that this Website, Research Services, information, content, materials, or any other material included on or otherwise made available to you through this Website, their servers, or electronic communication sent by the RA are free of viruses or other harmful components.

Nothing on this Website constitutes, or is meant to constitute, advice of any kind.

Indemnification: The client:

  1. Represents, warrants and covenants that no materials of any kind provided by him/her will:
    1. Violate, plagiarise, or infringe upon the rights of any third party, including copyright, trademark, privacy or other personal or proprietary rights; or
    2. Contain libellous, Prohibited Content or other unlawful material;
  2. Hereby agree to indemnify, defend and hold harmless the RA and all of the RA’s officers, directors, owners, agents, customers/clients, information providers, affiliates, licensors and licensees (collectively, the “Indemnified Parties”) from and against any and all liability and costs, including, without limitation, reasonable advocate’s fees, incurred by the Indemnified Parties in connection with any claim arising out of any breach by the client of these Terms or the foregoing representations, warranties and covenants. The client shall cooperate as fully as reasonably required in the defence of any such claim. The RA reserves the right, at its own expense, to assume the exclusive defence and control of any matter subject to indemnification by the client.

Applicable law: This Website, including the Content and Contributed Content and information contained herein, and the provision of Research Services shall be governed by the Securities and Exchange Board of India, laws of the Republic of India and the courts of Chennai, India which shall retain exclusive jurisdiction to entertain any proceedings in relation to any disputes arising out of the same. As such, the laws of India shall govern any transaction completed using this Website.

Information gathered and tracked: Information submitted or collected on the Website or pursuant to the use of the Services is stored in a database. Specifically, we store the username, name, e-mail address, contact number, as submitted or collected on our Website or through the provision of the Research Services. We may use such information to send out occasional promotional materials, including alerts on new Services available, or other promotional and marketing material relating to our clients and customers.

In accordance with the Information Technology Act 2000, the name and the details of the Grievance Officer at PrimeInvestor is provided below:

Mr. Srikanth Meenakshi
PrimeInvestor Financial Research Pvt. Ltd., Registered office: 659, 4th Avenue, D-Sector, Anna Nagar Western Extension, Chennai 600 101.
Email: [email protected]

11. Mandatory notice:

Clients shall be requested to go through Do’s and Don’ts while dealing with RA as specified in SEBI master circular no. SEBI/HO/MIRSD-POD-1/P/CIR/2024/49 dated May 21, 2024 or as may be specified by SEBI from time to time.

12. Optional Centralised Fee Collection Mechanism:

SEBI has operationalized a centralized fee collection mechanism for IA and RA. Under this mechanism, clients shall pay fees to IAs/RAs through a designated platform/portal administered by a recognized Administration and Supervision body. This is an optional mechanism for the registered entities. At this time, PrimeInvestor has opted out of this fee collection mechanism. Therefore, all subscription payments for the Research Services will be through the modes as specified in Clause 5 of these Terms.

Enter the OTP sent to (Edit)
By doing this you agree to our terms & conditions
Didn't receive OTP? Resend

Have an account?
Login To Your Account
OR
Don’t have an account ? Register for free